Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C22H26N3O4S.K |
| Molecular Weight | 467.623 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
[K+].CC1=C(OCC2COC(C)(C)OC2)C(C)=C(C[S@@+]([O-])C3=NC4=C([N-]3)C=CC=C4)N=C1
InChI
InChIKey=OCQCEUDEEZLGSQ-VNUFCWELSA-N
InChI=1S/C22H26N3O4S.K/c1-14-9-23-19(13-30(26)21-24-17-7-5-6-8-18(17)25-21)15(2)20(14)27-10-16-11-28-22(3,4)29-12-16;/h5-9,16H,10-13H2,1-4H3;/q-1;+1/t30-;/m1./s1
| Molecular Formula | C22H27N3O4S |
| Molecular Weight | 429.532 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
| Molecular Formula | K |
| Molecular Weight | 39.0983 |
| Charge | 1 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
E-3710 (Z-215) is a new proton pump inhibitor (PPI). E-3710 irreversibly inhibited H(+),K(+)-ATPase activity in pig gastric vesicles with an acidic internal environment. E-3710 is a long-acting inhibitor of gastric acid secretion and a promising novel therapy for acid-related diseases, such as gastroesophageal reflux disease. E-3710 is metabolized through oxidation, reduction and conjugation. Unchanged E-3710 was excreted in urine at trace levels but was not detected in faces. The major isozyme contributing to the oxidation of Z-215, including the formation of Z-215 sulphone, was CYP3A4. It is useful for treating gastroesophageal reflux disease in all CYP2C19 genotypes. E-3710 is in phase II clinical trial for the treatment of erosive esophagitis and gastro-esophageal reflux.
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| Mass balance and metabolism of Z-215, a novel proton pump inhibitor, in healthy volunteers. | 2018-10 |
|
| Pharmacokinetics and Pharmacodynamics of Azeloprazole Sodium, a Novel Proton Pump Inhibitor, in Healthy Japanese Volunteers. | 2018-04 |
|
| Efficacy and Safety Profile of Z-215 (Azeloprazole Sodium), a Proton Pump Inhibitor, Compared with Rabeprazole Sodium in Patients with Reflux Esophagitis: A Phase II, Multicenter, Randomized, Double-Blind, Comparative Study. | 2018 |
|
| E3710, a new proton pump inhibitor, with a long-lasting inhibitory effect on gastric acid secretion. | 2010-08 |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/30038671
Once a day within about 30 minutes after breakfast 10, 20, or 40 mg for 8 weeks
Route of Administration:
Oral
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 20:10:00 GMT 2025
by
admin
on
Mon Mar 31 20:10:00 GMT 2025
|
| Record UNII |
3N2UVX53J5
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
DTXSID601337399
Created by
admin on Mon Mar 31 20:10:00 GMT 2025 , Edited by admin on Mon Mar 31 20:10:00 GMT 2025
|
PRIMARY | |||
|
955095-50-8
Created by
admin on Mon Mar 31 20:10:00 GMT 2025 , Edited by admin on Mon Mar 31 20:10:00 GMT 2025
|
PRIMARY | |||
|
3N2UVX53J5
Created by
admin on Mon Mar 31 20:10:00 GMT 2025 , Edited by admin on Mon Mar 31 20:10:00 GMT 2025
|
PRIMARY | |||
|
126961808
Created by
admin on Mon Mar 31 20:10:00 GMT 2025 , Edited by admin on Mon Mar 31 20:10:00 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
PARENT -> SALT/SOLVATE |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |